SEARCH

SEARCH BY CITATION

References

  • Adams, D.J. , Sandvold, M.L. , Myhren, F. , Jacobsen, T.F. , Giles, F. & Rizzieri, D.A. (2008) Anti proliferative activity of ELACYT (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leukemia Lymphoma, 49, 786797.
  • Adema, A.D. , Laan, A.C. , Myhren, F. , Fichtner, I. , Verheul, H.M. , Sandvold, M.L. & Peters, G.J. (2010a) Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. International Journal of Oncology, 36, 285294.
  • Adema, A.D. , Losekoot, N. , Smid, K. , Kathmann, I. , Myhren, F. , Sandvold, M.L. & Peters, G.J. (2010b) Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells. Nucleosides, Nucleotides & Nucleic Acids, 29, 394399.
  • Adema, A.D. , Smid, K. , Losekoot, N. , Honeywell, R.J. , Verheul, H.M. , Myhren, F. , Sandvold, M.L. & Peters, G.J. (2011) Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Investigational New Drugs, 10.1007/s10637-011-9756-8 [Epub ahead of print].
  • Becker, P.S. , Kantarjian, H.M. , Appelbaum, F.R. , Petersdorf, S.H. , Storer, B. , Pierce, S. , Shan, J. , Hendrie, P.C. , Pagel, J.M. , Shustov, A.R. , Stirewalt, D.L. , Faderl, S. , Harrington, E. & Estey, E.H. (2011) Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. British Journal of Haematology, 155, 182189.
  • Bergman, A.M. , Kuiper, C.M. , Voorn, D.A. , Comijn, E.M. , Myhren, F. , Sandvold, M.L. , Hendriks, H.R. & Peters, G.J. (2004) Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochemical Pharmacology, 67, 503511.
  • Berry, D.A. (1989) Monitoring accumulating data in a clinical trial. Biometrics, 45, 11971211.
  • Berry, D.A. (2006) Bayesian clinical trials. Nature Reviews in Drug Discovery, 5, 2736.
  • Borthakur, G. , Huang, X. , Kantarjian, H. , Faderl, S. , Ravandi, F. , Ferrajoli, A. , Torma, R. , Morris, G. , Berry, D. & Issa, J.P. (2010) Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leukemia & Lymphoma, 51, 7378.
  • Breistol, K. , Balzarini, J. , Sandvold, M.L. , Myhren, F. , Martinsen, M. , De Clercq, E. & Fodstad, O. (1999) Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Research, 59, 29442949.
  • Burnett, A. , Wetzler, M. & Lowenberg, B. (2011) Therapeutic advances in acute myeloid leukemia. Journal of Clinical Oncology, 29, 487494.
  • Cheson, B.D. , Bennett, J.M. , Kopecky, K.J. , Buchner, T. , Willman, C.L. , Estey, E.H. , Schiffer, C.A. , Doehner, H. , Tallman, M.S. , Lister, T.A. , Lo-Coco, F. , Willemze, R. , Biondi, A. , Hiddemann, W. , Larson, R.A. , Lowenberg, B. , Sanz, M.A. , Head, D.R. , Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21, 46424649.
  • Chevallier, P. , Delaunay, J. , Turlure, P. , Pigneux, A. , Hunault, M. , Garand, R. , Guillaume, T. , Avet-Loiseau, H. , Dmytruk, N. , Girault, S. , Milpied, N. , Ifrah, N. , Mohty, M. & Harousseau, J.L. (2008) Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. Journal of Clinical Oncology, 26, 51925197.
  • Cortes, J. , Kantarjian, H. , Ball, E.D. , Dipersio, J. , Kolitz, J.E. , Fernandez, H.F. , Goodman, M. , Borthakur, G. , Baer, M.R. & Wetzler, M. (2011) Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer, 118, 418427.
  • Damaraju, V.L. , Sawyer, M.B. , Mackey, J.R. , Young, J.D. & Cass, C.E. (2009) Human nucleoside transporters: Biomarkers for response to nucleoside drugs. Nucleosides, Nucleotides & Nucleic Acids, 28, 450463.
  • Dueland, S. , Aamdal, S. , Lind, M.J. , Thomas, H. , Sandvold, M.L. , Gaullier, J.M. & Rasch, W. (2009) Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study. Acta Oncologica, 48, 137145.
  • Eom, K.S. , Min, W.S. , Kim, H.J. , Cho, B.S. , Choi, S.M. , Lee, D.G. , Lee, S. , Min, C.K. , Kim, Y.J. , Cho, S.G. , Lee, J.W. & Kim, C.C. (2010) FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. Medical Oncology, 28(Suppl. 1), 462470.
  • Fernandez Calotti, P. , Galmarini, C.M. , Canones, C. , Gamberale, R. , Saenz, D. , Avalos, J.S. , Chianelli, M. , Rosenstein, R. & Giordano, M. (2008) Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia. Biochemical Pharmacology, 75, 857865.
  • Galmarini, C.M. , Thomas, X. , Calvo, F. , Rousselot, P. , El Jafaari, A. , Cros, E. & Dumontet, C. (2002a) Potential mechanisms of resistance to cytarabine in AML patients. Leukemia Research, 26, 621629.
  • Galmarini, C.M. , Thomas, X. , Calvo, F. , Rousselot, P. , Rabilloud, M. , El Jaffari, A. , Cros, E. & Dumontet, C. (2002b) In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. British Journal of Haematology, 117, 860868.
  • Galmarini, C.M. , Myhren, F. & Sandvold, M.L. (2009) CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. British Journal of Haematology, 144, 273275.
  • Giles, F. , O'Brien, S. , Cortes, J. , Verstovsek, S. , Bueso-Ramos, C. , Shan, J. , Pierce, S. , Garcia-Manero, G. , Keating, M. & Kantarjian, H. (2005) Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer, 104, 547554.
  • Giles, F. , Verstovsek, S. , Garcia-Manero, G. , Thomas, D. , Ravandi, F. , Wierda, W. , Ferrajoli, A. , Kornblau, S. , Jabbour, E. , Shan, J. , O'Brien, S. , Albitar, M. & Kantarjian, H. (2006) Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. British Journal of Haematology, 134, 5860.
  • Giles, F. , Rizzieri, D. , Ravandi, F. , Swords, R. , Jacobsen, T.F. & O'Brien, S. (2012a) Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leukemia Research, 36, 7173.
  • Giles, F.J. , Vey, N. , Rizzieri, D. , Ravandi, F. , Prebet, T. , Borthakur, G. , Jacobsen, T.F. , Hagen, S. , Nilsson, B. & O'Brien, S. (2012b) Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematologic malignancies. Leukemia, Jan 6. doi: 10.1038/leu.2012.1. [Epub ahead of print].
  • Giovannetti, E. , Mey, V. , Loni, L. , Nannizzi, S. , Barsanti, G. , Savarino, G. , Ricciardi, S. , Del Tacca, M. & Danesi, R. (2007) Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacology Research, 55, 343349.
  • Hubeek, I. , Stam, R.W. , Peters, G.J. , Broekhuizen, R. , Meijerink, J.P. , van Wering, E.R. , Gibson, B.E. , Creutzig, U. , Zwaan, C.M. , Cloos, J. , Kuik, D.J. , Pieters, R. & Kaspers, G.J. (2005) The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. British Journal of Cancer, 93, 13881394.
  • Jin, G. , Matsushita, H. , Asai, S. , Tsukamoto, H. , Ono, R. , Nosaka, T. , Yahata, T. , Takahashi, S. & Miyachi, H. (2009) FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochemical Biophysical Research Communications, 390, 10011006.
  • Juliusson, G. , Antunovic, P. , Derolf, A. , Lehmann, S. , Mollgard, L. , Stockelberg, D. , Tidefelt, U. , Wahlin, A. & Hoglund, M. (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, 113, 41794187.
  • Kohrt, H.E. , Patel, S. , Ho, M. , Owen, T. , Pollyea, D.A. , Majeti, R. , Gotlib, J. , Coutre, S. , Liedtke, M. , Berube, C. , Alizadeh, A.A. & Medeiros, B.C. (2010) Second-line mitoxantrone etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. American Journal of Hematology, 85, 877881.
  • Litzow, M.R. , Othus, M. , Cripe, L.D. , Gore, S.D. , Lazarus, H.M. , Lee, S.J. , Bennett, J.M. , Paietta, E.M. , Dewald, G.W. , Rowe, J.M. & Tallman, M.S. (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. British Journal Haematology, 148, 217225.
  • Mackey, J.R. , Galmarini, C.M. , Graham, K.A. , Joy, A.A. , Delmer, A. , Dabbagh, L. , Glubrecht, D. , Jewell, L.D. , Lai, R. , Lang, T. , Hanson, J. , Young, J.D. , Merle-Beral, H. , Binet, J.L. , Cass, C.E. & Dumontet, C. (2005) Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood, 105, 767774.
  • Marce, S. , Molina-Arcas, M. , Villamor, N. , Casado, F.J. , Campo, E. , Pastor-Anglada, M. & Colomer, D. (2006) Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica, 91, 895902.
  • Montillo, M. , Ricci, F. , Tedeschi, A. , Cafro, A.M. , Nosari, A.M. , Nichelatti, M. , Marbello, L. & Morra, E. (2009) Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia. Leukemia Research, 33, 10721078.
  • Oguri, T. , Achiwa, H. , Muramatsu, H. , Ozasa, H. , Sato, S. , Shimizu, S. , Yamazaki, H. , Eimoto, T. & Ueda, R. (2007) The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Letters, 256, 112119.
  • Perl, A.E. , Kasner, M.T. , Tsai, D.E. , Vogl, D.T. , Loren, A.W. , Schuster, S.J. , Porter, D.L. , Stadtmauer, E.A. , Goldstein, S.C. , Frey, N.V. , Nasta, S.D. , Hexner, E.O. , Dierov, J.K. , Swider, C.R. , Bagg, A. , Gewirtz, A.M. , Carroll, M. & Luger, S.M. (2009) A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clinical Cancer Research, 15, 67326739.
  • Qin, T. , Jelinek, J. , Si, J. , Shu, J. & Issa, J.P. (2009) Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood, 113, 659667.
  • Sandvold, M.L. , Galmarini, C. , Myhren, F. & Peters, G. (2010) The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues. Nucleosides, Nucleotides & Nucleic Acids, 29, 386393.
  • Schimmer, A.D. , Estey, E.H. , Borthakur, G. , Carter, B.Z. , Schiller, G.J. , Tallman, M.S. , Altman, J.K. , Karp, J.E. , Kassis, J. , Hedley, D.W. , Brandwein, J. , Xu, W. , Mak, D.H. , LaCasse, E. , Jacob, C. , Morris, S.J. , Jolivet, J. & Andreeff, M. (2009) Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Journal of Clinical Oncology, 27, 47414746.
  • Stone, R.M. , Moser, B. , Sanford, B. , Schulman, P. , Kolitz, J.E. , Allen, S. , Stock, W. , Galinsky, I. , Vij, R. , Marcucci, G. , Hurd, D. & Larson, R.A. (2011) High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leukemia Research, 35, 329333.
  • Vardiman, J.W. , Thiele, J. , Arber, D.A. , Brunning, R.D. , Borowitz, M.J. , Porwit, A. , Harris, N.L. , Le Beau, M.M. , Hellström-Lindberg, E. , Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of. myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937951.
  • Wierzbowska, A. , Robak, T. , Pluta, A. , Wawrzyniak, E. , Cebula, B. , Holowiecki, J. , Kyrcz-Krzemien, S. , Grosicki, S. , Giebel, S. , Skotnicki, A.B. , Piatkowska-Jakubas, B. , Kuliczkowski, K. , Kielbinski, M. , Zawilska, K. , Kloczko, J. & Wrzesien-Kus, A. (2008) Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. European Journal of Haematology, 80, 115126.